Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer
Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies ...
GlobalData on MSN2d
EMA gives OMPD to Actuate’s pancreatic cancer therapy
Actuate Therapeutics has gained orphan medicinal product designation (OMPD) from the European Medicines Agency (EMA) for ...
Actuate Therapeutics announces EMA granted OMPD to elraglusib
Actuate Therapeutics (ACTU) announced that the European Medicines Agency, EMA, has granted Orphan Medicinal Product Designation, OMPD, to ...
Business Insider4d
Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer
CHICAGO and FORT WORTH, Texas, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage ...
Stockhouse3d
Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer
CHICAGO and FORT WORTH, Texas, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage ...
Investing25d
Actuate reports breakthrough in pancreatic cancer trial
CHICAGO and FORT WORTH, Texas - Actuate Therapeutics, Inc. (NASDAQ: ACTU), a biopharmaceutical company specializing in cancer treatment drugs with a market capitalization of $170 million ...
Nasdaq24d
Actuate Therapeutics, Inc. Reports Positive Phase 2 Trial Results for Elraglusib in Combination with GnP for Metastatic Pancreatic Cancer
Actuate Therapeutics, Inc. announced promising results from its Phase 2 trial of elraglusib combined with gemcitabine/nab-paclitaxel (GnP) for treating metastatic ...
Stockhouse24d
Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer
CHICAGO and FORT WORTH, Texas, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage ...
Investing24d
Actuate reports breakthrough in pancreatic cancer trial
CHICAGO and FORT WORTH, Texas - Actuate Therapeutics, Inc. (NASDAQ: ACTU), a biopharmaceutical company specializing in cancer treatment drugs with a market capitalization of $170 million, announced ...
Nasdaq24d
Actuate Therapeutics announces new data from Phase 2 trial of elraglusib
Actuate Therapeutics (ACTU) announced new positive data from its ongoing and fully enrolled randomized Phase 2 trial of elraglusib in combination with gemcitabine/nab ...
Finanznachrichten24d
Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer
The ongoing Actuate-1801 Part 3B study (NCT03678883) is a randomized, controlled Phase 2 trial of elraglusib with GnP versus GnP alone in first line mPDAC. The trial enrolled 286 mPDAC patients ...
manilatimes25d
Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer
CHICAGO and FORT WORTH, Texas, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) ("Actuate” or the "Company”), a clinical-stage biopharmaceutical company focused on ...